Surgical oncologists using current manual or robotic surgical oncology imaging workstation systems rely on inadequate visual inspections and tactile information during surgical tumor resection procedures.

The current intraoperative imaging modality with Near InfraRed-I (NIR-I) Fluorescence Image Guided Surgery (FIGS) for visualizing and removing tumor tissues with tumor cell-free margins is inadequate, with low-resolution images and poor patient clinical outcomes.

The NIR-I platform is rapidly becoming obsolete and is being replaced by NIR-II. Most non-invasive medical imaging modalities, such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and Infrared Fluorescence Image Guided Surgery (IRFIGS) are currently used in patients. 

IRFIGS data currently are not sufficiently high resolution nor tissue-penetrating for meaningful and easy
translation in the operating room; thus there is an unmet need for surgical planning and surgery, to
significantly improve patients’ clinical outcomes.

Minimally Invasive Surgery Imaging with IR* fluorescent targeted agents is especially important for:  

  1. Radical tumor resection with tumor margin assessment

  2. The detection of sentinel lymph nodes, the first draining nodes from the tumor

  3. Laparoscopic procedures where the surgeon lacks tactile information.